Floatz logo

Margetuximab

HER-2 Positive Breast Cancer

MacroGenicsmonoclonal_antibodyPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the HER-2 Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
National Taiwan University Hospital
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
National Taiwan University Hospital
Phase 3BB
Carboplatin
Instituto do Cancer do Estado de São Paulo
Phase 2/3BB
Inno-206
National Taiwan University Hospital
Phase 2BB
Trastuzumab Emtansine
Dana-Farber Cancer Institute
Phase 2/3BB

View all 25 →

Same molecule, other indications

Margetuximab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
HER2 positive breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →